Conversely, a phase I study (NCT02773459) exploring binimetinib (MEK1/2 inhibitor) and capecitabine in patients with advanced or metastatic CCA with RAS/RAF/MEK/ERK pathway alterations showed encouraging anti-tumor effects. The gene discussed is MAP2K7; the disease is neoplasm.